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A Tale of Two Standards: 
Drift and Inertia in Modern Korean Medical Law 
 
Shawn H.E. Harmon* and Na-Kyoung Kim* 
Abstract 
Like all nations, the national character of Korea has been shaped by a variety of 
geographic and historical factors.  Some of the characteristics that have emerged 
from Korea’s experience are ‘familism’ and ‘scientism’, both of which have had, and 
are having, a fundamental impact on the content and application of medical law.  
These phenomena, combined with recent events both inside Korea (eg: a physicians’ 
strike (2000) and the more important Hwang scandal (2005)) and outwith (eg: the 
spread of ‘informed consent’ (1980s), the commencement of the Human Genome 
Project (1990), and the cloning of Dolly the Sheep (1997)), have contributed to a 
flurry of recent governance activity in Korea.  Given the latest legislative proposals 
offered, we explore two areas of Korean medical law with a view to exposing their 
trajectories.  First, we examine the governance of the patient-physician relationship 
in the clinical setting, paying particular attention to consent and to liability.  Second, 
we examine the legal-ethical control of biotech research in the medical research 
setting, paying particular attention to consent, quality control and limits.  We 
conclude that these two arenas appear to be travelling down two dramatically 
different (if not divergent) roads; in the case of the former, drifting away from 
traditional practices, and in the case of the latter, remaining mired in imbalance and 
dominated by antithetical interests. 
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1. Introduction 
The national character of every country and its peoples is shaped by its unique 
physical and relational position in the world, and by its particular historic events and 
(national) responses to the consequences of those events.  Korea, of course, is no 
exception – modern Korea is a product of its geographical position (i.e. a small 
country between “four elephants”) and its past (i.e. a dynastic state recently subject to 
colonial rule, war, dictatorship, and, now, democratisation), and how they have 
shaped its people.  Of particular importance – from a medical law perspective – is 
Korea’s long-standing adoption of Confucian “familialism”,1 and its relatively recent 
but deep-rooted tradition of “sciencism”,2 both of which have endured to the present. 
The national “inclination” toward science, has, despite the Confucian roots of, and 
social characteristics that still pervade, Korean society, encouraged the rapid uptake 
of high-tech medical equipment,3 and the aggressive pursuit of biotechnology 
development,4 both of which have had an indelible impact on medicine and healthcare 
in Korea, the former within the clinical setting and the latter in the research setting.  
Additionally, these sci-tech trajectories have contributed to schisms and scandals 
which have further shaped these settings (clinical and research) and the legal 
structures designed to govern them. 
Given the above, this article explores Korean “medical law”5 as it pertains to the 
clinical and research settings, focusing on recent controversial reforms that have been 
pursued within them.  Part 2 considers the governance of the patient-physician 
relationship in the clinical setting, paying particular attention to consent, which 
implicates Confucian traditions, “technologisation” trends, medical accidents and 
therefore liability.  Part 3 considers the legal-ethical control of biotech research in the 
medical research setting, paying particular attention to consent, quality control and 
                                               
1
 This term is further elaborated in Part 2.1 below, but generally refers to the perceived importance of 
family cohesion and continuity and the impact that predilection for deferment to family hierarchy has 
had: see IH Park & LJ Cho, “Confucianism and the Korean Family” (1995) 26 Journal of Comparative 
Family  Studies 117-134. 
2
 This term refers to the national inclination to rely on science as a means of regeneration and 
competition with existing (and colonising) powers, and to elevate science to a national imperative 
tangled up with nationalism: see SY Song, “The Rise and Fall of Embryonic Stem Cell Research in 
Korea” (2006) 9 Asian Biotechnology and Development Review 65-73, who, at 70, notes that science 
has consistently been associated with nation-building and economic growth. 
3
 B M Yang, “Medical Technology and Inequality in Health Care: The Case of Korea” (1993) 8 Health 
Policy Planning 385-393. 
4
 SY Song, see note 2. 
5
 Here understood as that collection of regulatory instruments which govern the practice of medicine, 
including liability for medical negligence, and medical research and biotechnologies. 
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limits.  We suggest that recent activities have been influenced by Korea’s “scientism”, 
but that this phenomenon has led the two different settings on divergent paths.6 
 
 
 
2. The Clinical Setting: Consent, Liability and Recent Governance 
Activity 
In this Part, we explore two elements of the modern clinical experience.  First, we 
examine the roots of the patient-physician relationship, followed by its current and 
(potential) future status, paying particular attention to the Medical Services Act 1951,7 
(MSA 1951) and related instruments.  Second, we examine clinical practice in light of 
new medical technologies and the recent legislative reform proposals that the new 
complexity of clinical practice has spawned.  The purpose of both investigations is to 
consider the position of Korean patients and physicians, focusing particularly on the 
latter’s exposure to legal liability. 
2.1 ‘The Corrections’ – Confucianism, Consent and Physician Liability 
Like patients in almost every country around the world, Korean patients have often 
struggled to make their voices heard.  This is not only true from a public health and 
health policy perspective, but also from a more personal, relational perspective where 
“paternalism” and “familialism” have long reigned supreme.  This Section considers 
the Confucian origins of the modern patient-physician relationship, and recent 
legislative changes that are transforming that relationship. 
2.1.1 ‘A Sentimental Journey’ – Traditional Approaches to Consent and the Patient-
Physician Relationship 
Korea has been fundamentally influenced by “Confucianism”, an ancient philosophy 
imported from China which rests on five virtues, namely ren (benevolence, altruism, 
humanity), yi (integrity, uprightness), li (propriety, boundaries, rite), chi (moral 
understanding, self-cultivation), and shin (honesty, trust), and five principle 
relationships (eg: government-citizen, parent-child, husband-wife, older sibling-
younger sibling, and friend-friend), and through which individuals find identity, duty 
and responsibility.8  Within this belief-system, family cohesion and continuity are 
seen as central pillars; they are seen as essential for sustaining the community and the 
state. 
                                               
6
 And we draw on SD Yi, Biotechnology and Law (Seoul: Dae Woo Acanet, 2003), throughout.  See 
also NK Kim, “Biotechnology and Law” (2004) 90 Archiv für Rechts und Sozialphilosophie 457-460, 
which reviews the introduction to this book. 
7
 Law No. 8651, adopted in 1951, last amended 17 October 2007, available at http://www.moleg.go.kr 
and http://www.lawkorea.com. 
8See K’ung Fu-Tzu, The Analects, China, circa 500 BCE, available at 
http://classics.mit.edu/Confucius/analects.html.  For a discussion of these elements of Confucianism, 
see MJ Park & C Chesla, “Revisiting Confucianism as a Conceptual Framework for Asian Family 
Study” (2007) 13 Journal of Family Nursing 293-311. 
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This social construction (or ethic) is manifestly relevant to medical practice and 
indeed influenced the development of medicine and medical practice throughout 
Asia.9  One of the more enduring ways it has influenced practice has been to reinforce 
traditional familialism, which is characterised by familial solidarity and paternalism 
within an extended family, which family lives together, and has responsibilities and 
status allocated according to sex and age.10  By doing so, it has coloured the clinical 
relationship, requiring family determination, presupposing an objective conception of 
the good, and upholding the value of harmonious dependence.  The general construct 
can be described as follows: Every agent should be able to make his or her decisions 
and actions harmoniously in cooperation with other relevant persons.11 
In short, familialism has emphasised hierarchical authority over individualism, not 
unlike paternalistic Western practices, which have only recently been thrown over by 
the rise of individual autonomy, and this conception has shaped the clinical 
relationship in many ways, not least through the structuring of practices for obtaining 
consent to medical treatment in the clinical setting.  Thus, in addition to the patient, 
family members (eg: spouse, parents, adult children) are very important to the consent 
process, often retaining final authority: 
[W]hen a patient requests or refuses a treatment while a relevant 
family member holds an opposite opinion, the physician generally 
should not simply follow the patient’s wish as in the West, even if 
the patient is evidently competent.  Instead, the physician should tell 
the patient and the family members to negotiate and provide an 
agreement to him before he can undertake a medical act.12 
The importance of family in the clinical setting is exemplified by the Korean Organ 
Transplantation Act 1999.13  Subsection 18(3) of that Act stipulates that, although the 
brain dead or deceased person gave consent for the extraction of her organs when she 
was competent, her family or survivors can nonetheless refuse consent for the 
extraction, which refusal must be honoured.  Conversely, if there is no evidence of 
consent or refusal prior to brain death or death, but the family consents to extraction, 
then the extraction is legal.  Section 3 of the Act defines “family or survivors” as the 
spouse, the lineal descendant, the lineal ascendant, brothers and sisters, and, if none of 
the others exist, a family relative (eg: cousin). 
                                               
9
 K Hattori, “East Asian Family and Biomedical Ethics” in SY Song, YM Koo & D Macer (eds.), Asian 
Bioethics in the 21st Century (NZ: Eubios, 2003) 229-231. 
10R Chau & WK Yu, “Is Welfare UnAsian?”, 21-45, at 35, and SH Ahn & SC Lee, “The Development 
of the South Korean Welfare Regime”, 165-186, at 166, both in A Walker & CK Wong (eds.), East 
Asian Welfare Regimes in Transition: From Confucianism to Globalisation (Bristol: Policy Press, 
2005). 
11R Fan, “Self-Determination vs. Family-Determination: Two Incommensurable Principles of 
Autonomy” (1997) 11 Bioethics 309-322. 
12
 R Fan, ibid, at 316-317. 
13
 Law No. 8852, adopted in 1999, last amended in 2008, available at http://www.moleg.go.kr and 
http://www.lawkorea.com. 
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The physician also has an important role to play in this Confucian-informed 
relationship.  It is the physician’s duty to promote the objective conception of the 
good: 
What is important is not that one’s clinical decisions must be made 
by oneself in conformity with one’s present desires.  It is more 
important that they are made for one’s long-term good impersonally 
understood. … This features significantly discounts patients’ 
presently-held desires, preferences or expectations if they do not fit 
into the objective conception of the good.  For instance, if a patient 
refuses treatment because he judges his life is no longer worth 
living, while the relevant others do not think so in terms of the 
objective conception of the good, the patient’s wish would not be 
followed, whether or not the patient is competent.14 
In short, under traditional practices, the physician’s duty was to promote the objective 
conception of the good whether the patient wished it or not. 
2.1.2 ‘Such a Long Journey’ – From Confucian Tenets to Statutory Guidance 
Although Confucianism continues to be important in Korea, its power is diminishing, 
both generally and in the medical context,15 and relationships like that described 
above are less common.  For example, note the Boramae Hospital case,16 in which the 
family of a patient recovering from brain surgery convinced the physician that the 
objective good, which was largely informed by financial matters, demanded that 
treatment be discontinued and the patient be discharged to recover at home.  Despite 
knowing that discharge would almost certainly kill the patient, the physician 
acquiesced.  The patient died almost immediately after arriving home.  The Korean 
Supreme Court affirmed the decision of the lower courts to convict the physician for 
accessory to murder (and the patient’s wife of murder).  Although this case is 
primarily about improper motive and physician dereliction of duty, it demonstrates 
the diminishing relevance of old conceptions of familial consent, clarifies the duties 
expected of family in circumstances where the patient is incompetent, and upholds the 
claim that the patient’s best interests should be paramount.17  In the aftermath of this 
case, hospitals have become reluctant to discharge patients with low survivability 
despite family desires. 
In circumstances where there is no question of incompetence, the patient is now 
considered a key decision-maker.  And this is certainly the case in situations governed 
by statute, which increasingly reflect international norms and Western influenced 
conceptions of individualism.  Of course, some physicians resist statutory guidance, 
viewing the management of the patient-physician relationship and the taking of 
consent as professional matters which should, at best, be governed by professional 
                                               
14
 R Fan, see note 11, at 318. 
15
 SH Ahn & SC Lee, see note 10, at 165 and 167. 
16
 24 June 2004, 2002 Do 995 (Kor SC). 
17
 This should not be taken to mean that all manner of paternalism is evaporating in Korea.  Some 
would argue, including the authors, that there has been a shift to another form of paternalism where 
courts (or the state) acts on behalf of the individual – a form of national paternalism. 
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codes.18  Unfortunately for these physicians, their arguments have fallen on deaf ears 
and the taking of “informed consent” is mandated by statute in a growing number of 
circumstances.19 
 
Modern Korean practice is governed by a number of instruments, perhaps the most 
important one being the MSA 1951, which was amended in its entirety just once 
(1973), but has subsequently been revised on a more piece-meal basis, first in 
response to the needs of modernisation, then to changes to the medical insurance 
system, and finally as a result of pressure from civil society proponents who have 
become more active/vocal under the new democratic regime.20  The primary function 
of the MSA 1951 is to structure and guide the practice of medicine and related 
activities in Korea, and thereby improve national health.  In doing so, it addresses the 
following: 
• qualifying and licensing physicians and establishing physician rules; 
• establishing and managing medical institutions; 
• introducing new medical techniques; 
• controlling medical advertising; 
• evaluating and overseeing medical institutions and practices; and 
• mediating medical conflicts and complaints. 
It stipulates that physicians shall seek the improvement of national health and 
contribute to securing the health of citizens (s. 2(2)).  Physicians, who must be 
qualified and licensed, are directed to provide treatment and health guidance (s. 
2(2)(1)), and to that end are instructed to keep records of medical treatment and to 
protect the confidentiality of those records (ss. 20 and 21), and to inform patients or 
their custodians about treatment and recuperative matters (s. 22).  Aside from this 
bland informational provision, the MSA 1951 does not specifically address the 
consent process. 
However, s. 9 of the Emergency Medical Services Act 1994,21 states that emergency 
medical personnel should, prior to taking action, explain the emergency medical 
intervention to the patient.  The taking of consent can be put off when (1) the patient 
is incompetent, or (2) such explanation would delay the necessary emergency 
treatment and thereby cause serious risk of loss of life or serious mental or physical 
disability.  Similarly, s. 12 of the Basic Bill of Medical Health Care 2000,22 states that 
everyone has the right to self determination, and to be informed sufficiently by his or 
                                               
18
 See SY Yun et al., “Consent for Emergency Patients: How Far Must We Go?” (2005) 16 Journal of 
the Korean Society of Emergency Medicine 164-170, who conducted a study of emergency physicians. 
19
 DY Hyun, “Legal Issues Concerning Informed Consent” (2005) 48 Journal of the Korean Medical 
Association 881-885. 
20
 For more on the rise of civil society as a political force in Korea, particularly as it relates to welfare 
infrastructural creation and reform, see SH. Ahn & SC. Lee, see note 10.  The question of whether civil 
society organisations are moving Korean policy in an appropriate direction, particularly in the medical 
field, is very much a matter of debate.  
21Law No. 8692, adopted in 1994, last amended 14 December 2007, available at 
http://www.moleg.go.kr. 
22Law No. 6909, adopted in 2000, last amended 29 May 2003, available at http://www.moleg.go.kr. 
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her physician about the therapy intended to be administered, whether for disease, 
transplantation or research, and to consent to the intervention prior to action being 
taken.  These provisions make clear that patients have rights to information and to 
consent (or refusal of consent), but they are limited to very particular settings (eg: 
Emergency Medical Services Act 1994) or declaratory instruments (eg: Basic Bill of 
Medical Health Care 2000). 
 
In the absence of broader consent guidance, new concepts have emerged which strive 
to articulate better the nature and purpose of “medical therapy” and the role of 
“autonomy” therein.  For example, the therapeutic relationship has now been 
characterised as an interaction in which both patient and physician have personal and 
co-dependent rights and duties.  In this approach, the patient-physician relationship is 
seen as a kind of conversation or “therapeutic communication” between patient and 
physician.23  Although patients lack medical training and knowledge, and are 
therefore unevenly empowered within this conversation, their vulnerability is seen as 
a promoter of responsibility in the physician, who is expected to appreciate the 
imbalance, and to empathise with the patient’s feelings and emotions, and to offer and 
then act on his or her best judgment.  Within this construct, the patient’s 
psychological and physical status determines, in a meaningful way, what s/he is told 
about the diagnosis, treatment course, alternatives and prognosis, the idea being that 
to disclose everything would be to shift the medical decision onto the patient thereby 
raising the possibility that the patient may experience “informed isolation and 
abandonment” (ie: patients would be dissatisfied if they were regarded as totally 
independent subjects within a medical decision-making framework).24  Ultimately, 
patients need information and some control, but they still need protection. 
This interpretation of the therapeutic relationship (and autonomy within it) constitutes 
a bridge between traditional practices and stark statutory statements, attempting to 
avoid the worst authoritarian elements of old Confucian approaches, and the most 
damaging individualistic elements of newer conceptions, which appear to be 
informing recent statutory reforms.25  The provisions of the Emergency Medical 
Services Act 1994 and the Basic Bill of Medical Health Care 2000, certainly offer the 
legal space within which this conception of the therapeutic communication could 
function insofar as they promote conditions, which facilitate understanding and 
encourage free discourse.26 
                                               
23See SD Yi, The Medical System and Law (Seoul: Korea University Press, 2000), who coined the term 
“therapeutic communication” in the Korean context and drew on Habermas in doing so.  
24
 See NK Kim, “Informed Consent in the Medico-Legal Context” (2007) 15 Korean Journal of 
Medical Law 10-14, and see J. Dichgans, “Der Arzt und die Wahrheit am Krankenbett” in L. 
Honnefelder et al., (eds.), Ärztliches Urteilen und Handeln (Frankfurt: Insel-Verlag, 1994) 194, who 
coined the phrase “informed isolation and abandonment”. 
25
 DY Hyun, see note 19. 
26
 SD Yi, “The Patient’s Rejection of Treatment and the Doctor’s Responsibility” (1998) 22 Korean 
Journal of Legal Medicine 95-99. 
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2.1.3 ‘Red Storm Rising’ – Amendments and Dissatisfaction 
It has now been suggested that a clearly articulated duty to inform should be included 
in Korea’s fundamental medical instrument (ie: the MSA 1951).  In May 2007, the 
Ministry of Health, Welfare and Family Affairs (MOHWFA) submitted to the 
National Assembly a wholly amended text for the MSA 1951.27  One of the most 
controversial reforms in this collection of amendments, from a practitioner’s point of 
view, is the establishment of a “duty to explain” as part of the consent process.  For 
example, s. 3(ii) of the draft states that medical professionals should explain the 
condition and the therapeutic methodology “to the person under his or her care”.28  
Although the provision would only be in the declarative part of the law, its presence 
combined with recent judicial trends (see below) would be to emphasise physician 
duties to explain to the satisfaction of the patient any treatment/procedure patients 
receive, including the risks associated with treatment, the risks of non-treatment, and 
alternative treatment options, and to thereafter seek the consent of the patient before 
any medical intervention is undertaken. 
The introduction of this “new” duty provoked sharp opposition from Korean medical 
professionals, who advanced a number of arguments against it and other reforms.  
First, they argued that, despite being contained in the declarative section of the draft 
law, this provision would accelerate the tendency to initiate lawsuits against doctors, 
and, in the long run, would lead to the inclusion in Korea’s medical law of sanctions 
against doctors who failed to meet the duty.29  Second, they argued that the imposition 
of such a duty hinted at a legislative blindness to both the reality of medical practice 
in Korea and the special relationship between physicians and patients.  While not 
denying the existence or value of autonomy as a principle (or indeed of consent as a 
practice), they argued that a provision explicitly imposing a duty to explain to the 
patient was contrary to long-standing practice, and would inject distrust into the 
doctor-patient relationship.30 
The inclusion of a duty to explain in Korea’s fundamental medical-legal instrument 
throws into much sharper perspective the requirements of consenting individual 
patients, and would appear to bring Korean legislation ever closer to the widely 
recognised concept of autonomy, which finds its origins in Kantian notions of human 
dignity and the premise that every person has the right to have his/her bodily integrity 
                                               
27
 Draft No. 17-6615.  The text for the amendments can be found on the website of the new Ministry 
for Health, Welfare and Family Affairs, at http://www.mohw.go.kr/user/tdf. 
28
 This amendment is the most recent in a series, which has served to quantitatively increase the volume 
of regulation governing medicine. For example, from 1951-2001, the number of letters in the law 
increased 6-7%, whereas from 2001-2007, it increased by 21% and the number of provisions increased 
some 30%: see SD Yi, “The Direction of the Amendment of the Medical Services Law”, presented at 
“Principles and Prospects of Medical Law”, Conference, 23 November 2007, Sungshin Women’s 
University, Seoul, who argues that the change in the Medical Services Law as a method to 
systematization of social security medicine is expressed in these quantitative increases. 
29
 For more on these points, see Human Rights & Justice Committee, Korean Bar Society, Report of 
Symposium on the Amendment of Medical Services Law, 22 March 2007, available at 
http://www.koreanbar.or.kr. 
30
 With respect to practice, a recent study has demonstrated that many medical actions, including the 
giving of anaesthesia, which is a relatively high-risk action, are not preceded by information disclosure 
and consent: JY Sim et al., “Survey of the Informed Consent for Anaesthesia Practice in Korea” (2005) 
48 Korean Journal of Anesthesiology 117-123. 
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protected against invasion by others,31 and which has underwritten the concept of 
“informed consent”, a term which was “invented” in the US,32 made its way to the 
UK,33 and eventually surfaced in Korea.34  Despite judicial resistance to its inexorable 
expansion in a number of jurisdictions,35 its use as a means to found medical 
negligence suits on the basis of non- or inadequate-disclosure cannot be denied.  
Thus, for example, in Chester v Afshar,36 the UK House of Lords confirmed that an 
action will lie against a physician where consent is tainted by reason of inadequate 
disclosure of information.  In setting out the burden on the aggrieved patient basing an 
action on inadequate information disclosure, the House of Lords reaffirmed the 
significance of autonomy, holding that all material risks of a procedure (as determined 
by a responsible body of medical opinion) must be disclosed if the patient’s right to 
choose was to be protected.37  It further confirmed that, though a physician might, in 
appropriate circumstances, withhold information that might be considered 
psychologically damaging to the patient, this privilege is extremely circumscribed.38 
As it went in the UK, so it followed in Korea, where the concept of “informed 
consent”, if not the term itself, has already been used to found liability against 
physicians.  Generally, where there has been a failure to explain, the courts have 
found liability.  For example, in Hong v H-Hakwon,39 wherein a patient suffered from 
an undisclosed but not uncommon drug complication, the Korean Supreme Court held 
that it is part of the physician’s duty to inform the patient in advance about the 
method and means of treatment, its necessity, foreseeable risks, and prognosis.  In 
determining what information to provide, the physician should take into consideration 
things that would be important to the patient.  If the patient suffers an injury from a 
risk that was not disclosed, then one can claim emotional distress as a result of the 
injury.  Thus, even if it is found that the injury was not caused by the physician’s 
negligence, the fact of its foreseeability and non-disclosure makes it compensable 
                                               
31
 See J Mason & G Laurie, Mason & McCall Smith’s Law and Medical Ethics, 7th ed. (Oxford: OUP, 
2006) at 395.  Indeed, the premise that everyone has a right to bodily integrity has been recognised 
internationally as a human right: see YF v Turkey (2004) 39 EHRR 24 (ECHR), wherein it was held 
that Article 8 of the European Convention on Human Rights protects the physical and psychological 
integrity of the person, and that (compulsory) medical interventions represent an interference with this 
right. 
32
 See Salgo v Leland Stanford Junior University Board of Trustees (1957) 317 P 2d 170 (Cal CA). 
33
 It was first mentioned in the UK in Chatterton v Gerson, [1981] 1 All ER 257 (QB). 
34
 An early case of acknowledgement in Korea is Cha v Il-Song Hakwon, 28 April 1987, 86 Da Ka 
1136 (Kor SC). 
35
 See Rogers v Whittaker (1992), 109 ALR 625 (HC) in Australia, Sidaway v. Board of Governors of 
the Bethlem Royal Hospital, [1984] 1 All ER 1018 (CA) and Re T (adult: refusal of medical treatment), 
[1992] 4 All ER 649 (CA) in England, and Moyes v Lothian Health Board, [1990] 1 Med LR 463 (Ct 
Sess) in Scotland. 
36
 [2004] 4 All ER 587 (HL). 
37
 Lord Steyn, at para 14, states: “Surgery performed without the informed consent of the patient is 
unlawful.  The court is the final arbiter of what constitutes informed consent.” 
38
 A proposition which was made clear in Sidaway v Board of Governors of the Bethlem Royal 
Hospital, [1985] 1 All ER 643 (HL). 
39
 15 April 1994, 92 Da 25885 (Kor SC). 
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insofar as it causes emotional distress to the patient.  In Jeon et al. v Kim,40 the Court 
reaffirmed that a patient is entitled to at least nominal compensatory damages for the 
emotional distress of losing the right of self-determination.  A patient need only prove 
the fact that the physician provided no or insufficient information to her for liability to 
follow; she need not demonstrate a causal relationship between the medical act and 
the injury which triggered the emotional distress. 
As these and other cases demonstrate, regardless of whether one resists the term 
“informed consent”, information must, in the modern setting, pass from physician to 
patient, and where that information disclosure is inadequate, a case of medical 
negligence might follow.41  Moreover, these cases suggest that Korea may be moving 
in an explicitly autonomy-founded direction (as exemplified in the UK by Chester v 
Afshar), though it is still be too early to claim that autonomy-based arguments will 
expel (modified) Confucian concepts.  For its part, the draft amendment to the MSA 
1951 does little to elucidate the extent of the disclosure (what particular details 
should/must be divulged) or by what general standard that information should be 
judged when conflicts arise.42  In the absence of such guidance in support of this 
mechanism, which is often viewed uncomfortably by the profession, it is perhaps 
understandable that physicians feel at greater risk of litigation than ever before, 
particularly in light of the fact that the number of medical negligence lawsuits based 
on the failure to obtain proper “informed consent” is already on the rise in Korea.43 
2.2 ‘The Difference Engine’ – Technology, Complexity and Physician Liability 
The increasing insinuation of medical technologies into this personal, clinical 
relationship has made the struggle against liability all the more difficult, putting 
strains on practices such as “informed consent”, and frameworks such as the “patient-
physician relationship”.44  This Section considers the technological changes that have 
been occurring within Korean medical practice, and the concomitant legal 
vulnerability of physicians practicing “at the coal face” (ie: in the clinical setting). 
2.2.1 ‘Great Expectations’ – New Technologies in Healthcare Delivery 
The technologisation of Korean medical practice began in the 1980s and accelerated 
in the late ‘80s and ‘90s as a result of a desire by the new democratic government to 
be “modern”.45  Examples of new technologies that have been taken up include 
computer tomography scanners (CTs), magnetic resonance imagers (MRIs), ultra-
sonographs, automated chemical analysers, gamma cameras, linear accelerators, and 
the use of sophisticated healthcare information systems.  Adoption rates for such new, 
                                               
40
 10 February 1995, 93 Da 52402 (Kor SC). 
41
 As asserted by J Mason & G Laurie, see note 31, at 397. 
42
 For more on how these issues have been approached in the UK, see J Mason & G Laurie, ibid, at 
397-399. 
43SY Yun et al., see note 18. 
44
 BM Yang, see note 3. 
45
 A Son, “Modernization of Medical Care in Korea (1876-1990)” (1999) 49 Social Sciences and 
Medicine 543-550, and JG Kim & D Bates, “Results of a Survey on Medical Error Reporting Systems 
in Korean Hospitals” (2006) 75 International Journal of Medical Informatics 148-155. 
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high cost technologies (mostly imported from Germany, Japan, the Netherlands and 
the USA) jumped dramatically with the introduction of national health insurance,46 
and were such that during the 1990s the growth rate in Korean health spending was 
two-times higher than the average of all OECD countries.47  More recently, that 
growth rate has been supported by pharmaceutical spending. 
Obviously, the introduction of medical technologies can improve the quality of 
healthcare; they can enhance the effectiveness of treatments and the efficiency of 
procedures.  However, perhaps counter-intuitively, an increasing reliance on high 
technology in medical practice can also (1) reduce the quality (and equality) of care, 
and (2) increase the difficulty of recovering damages when one is injured by a 
medical procedure, both of which have been experienced in Korea. 
With respect to the first concern, medical technologies are only useful if physicians 
are trained to use them appropriately and to interpret their outputs properly.  
Unfortunately, there has been a lag in the adoption of training programmes and 
implementation policies for many of the new technologies.48  Related to this, there has 
been a lag in the ability of physicians to integrate their proper use into clinical 
practice.49  The problems associated with technology are compounded in Korea by the 
operation of a dual medical system, with traditional herbal physicians in one branch, 
and Western trained physicians in the other (often antagonistic) branch.  Indeed, the 
latter have reported that, despite a government order directing the traditionalists – 
who have a lack of technical training – to desist from using new technologies in their 
practice, they have continued to use them.50  Consequently, they say, there have been 
medical accidents based on the misuse of technology, though it seems more likely that 
responsibility for the medical accidents to which technology has contributed is shared 
between the two factions. 
The embedding of technologies into clinical settings (or treatment systems) has also 
contributed to the second concern – complexity and responsibility for medical 
injuries.  It is well recognised that, in modern technologically-driven and team-
delivered medical practices, accidents often result from adverse events that are 
complex.51  As such, it can sometimes be impossible to determine the causes of the 
accident for purposes of attributing legal liability.  Compounding the problem, very 
few Korean hospitals have any sort of official channel through which to report 
medical errors.52  As a result, patients face significant hurdles when trying to recover 
from injuries they sustain during treatment. 
                                               
46
 BM Yang, see note 3. 
47OECD, “OECD Health Data 2007: How Does Korea Compare” (2007), available at 
http://www.oecd.org/dataoecd/46/10/38979986.pdf [3 April 2008]. 
48
 For an example of the difficulty of integrating new and high-tech services into general practice, see 
YR Um, “A Critique of a ‘Wrongful Life’ Lawsuit in Korea” (2000) 7 Nursing Ethics 259-261. 
49
 See BM Yang, see note 3, who assesses the situation in the context of MRI utilisation. 
50
 Korean Medical Association, The 85-Year History of the Korean Medical Association (Seoul: KMA, 
1993), at 158. 
51JG Kim & D Bates, see note 45, and J Dew, “Using Root Cause Analysis to Make the Patient Care 
System Safe” (2002), at http://bama.ua.edu/~st497/UsingRootCauseAnalysis%20.htm [2 April 2008]. 
52
 JG Kim & D Bates, ibid, who, at 151, report that only 3% of Korean hospitals use their healthcare 
information systems for medical error reporting. 
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2.2.2 ‘The Battle of Life’ – Legal Responses to Medical Injuries 
Against the above background of technologies, team healthcare delivery and 
complexity, it has been reported that the percentage of patients who have successfully 
recovered for injuries suffered as a result of medical accidents has declined markedly 
since the 1990s, partially because courts are less sympathetic and are making greater 
evidentiary demands on patients.53  Bearing this in mind, particularly the difficulties 
faced by those who have been injured in proving physician liability for their loss, the 
Medical Accidents Compensation Bill54 was introduced. 
Proposed in 2005-2006 by certain members of the National Assembly and supported 
by certain NGOs,55 the controversial Medical Accidents Compensation Bill addresses 
civil remedies (eg: monetary compensation) for injuries suffered during medical 
interventions.  Perhaps the most radical provision in the Bill is s. 4, which states that 
the medical institution is liable for any injury to body, life or property caused by the 
medical treatment provided by a healthcarer belonging to the institution, unless the 
institution can prove that the healthcarer did not breach the standard of care expected 
of him/her, and that there was no problem with the equipment, procedures or human 
resources with respect to the event complained of. This provision essentially reverses 
the burden of proof in medical lawsuits, shifting it from the complainant patient to the 
defendant physician (or his/her employer).  In short, physicians would always bear the 
burden of proving that damage following on from a medical accident was not caused 
by his/her negligence.56 
Supporters of the Bill rallied around the slogan, “the sufficient guarantee of patients’ 
rights”, and justified the introduction of a reverse onus on the basis that patients face 
daunting hurdles in their efforts to prove fault on the part of medical practitioners, and 
thus often fail to win any or sufficient compensation when it might nonetheless be 
justified.  Indeed, they argued that proving liability against physicians is well nigh 
impossible.  As such, in addition to having limited medical knowledge or insight, 
                                               
53
 SC Kwon, “Winning a Medical Suit is No Easy Operation”, 28 March 2008, JoongAng Daily, 
available at http://joongangdaily.joins.com/article/view.asp?aid=2887842 [3 April 2008]. 
54The idea of this Bill was first discussed some 15 years ago, and a draft, Bill 3596 (Draft No. 17-
3596), was finally proposed by Assemblyman KW Lee on 8 December 2005.  Another draft, called the 
Medical Mediation Bill, No. 4413, was proposed by a small group led by Assemblywoman MO. Ahn 
on 23 May 2006, but for purposes of this paper this latter Bill is not the most interesting Bill and will 
not be referred to further. 
55The most prominent NGO, the Citizens’ Coalition for the Establishment of the Medical 
Compensation Act, was formed in October 2005 and remains active.  It is a coalition of a number of 
NGOs who wished to advance a common objective, including the Citizens’ Coalition for Economic 
Justice, the Consolidation for Medical Consumers, the Health Rights Network, the YMCA Seoul, and 
more. 
56
 This approach should not be confused with a “no-fault” system or a “strict liability” system, both of 
which are very different frameworks.  It is unclear how onerous the burden placed on the physician 
would be.  For example, it is not known whether it would simply be a matter of res ipsa loquitur such 
that, in order to discharge the burden, the physician need only demonstrate that there is at least one 
other reasonable explanation for the adverse outcome which does not require negligence.  Presumably, 
jurisprudence would have clarified this point. 
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patients have to rely, from an evidentiary perspective, on the physician-recorded chart 
notes concerning diagnosis, treatment and physician-patient exchanges.57 
The proposed provision, more than any other legislative initiative in the modern era, 
evinces an erosion of the gilded position of physicians in Korean society.58  It runs 
contrary to the principle, well established in Korea and beyond, that one cannot 
without further evidence infer medical negligence (or non-fulfilment of medical 
obligations) simply from the outcome of the intervention.59  Indeed, the provision 
represents such a shift in theory and precedent that, in the National Assembly debates, 
the MOHWFA spoke out against it, claiming that it might increase litigation against 
physicians, particularly if, as envisioned, it removed medical mediation as a necessary 
prerequisite to litigation.60  Additionally, the Chief of the Medical Policy Unit within 
the MOHWFA, stated that, “it is unforeseeable as to what kind of influence this draft 
would cause because of the variety, complexity and professionalism of the medical 
services.”61 
2.3 Summary & Conclusion: Principle Drift in the Clinical Setting 
Governance structures and governing principles associated with medical practices in 
the clinical setting have largely conformed to cultural concepts of propriety in the 
physician-patient relationship.  However, there has been a recent flurry of legislative 
activity in this arena (including the proposed amendments to the MSA 1951 and the 
Medical Accidents Compensation Bill), which suggest a “drift” in principles and a 
“vulnerability” on the part of physicians.  The MSA 1951 amendments introducing a 
“duty to explain” are suggestive of a “drift” from old characterisations of the 
physician-patient relationship to new ones, which are informed to a greater extent by 
international constructs.  They are evidence of a turning away from old (authoritarian) 
ideals, and this has been reproduced and given explicit voice in Korea’s medical law 
as it pertains to the clinical setting.  The introduction of the Medical Accidents 
Compensation Bill is also suggestive of a “drift” from old ways of dealing with 
interventions which result in harm to a new regime which reverses traditional burdens 
of proof such that defendant physicians face greater evidentiary hurdles and therefore 
greater legal vulnerability. 
It should be noted, however, that the National Assembly’s Committee for National 
Health and Welfare have not made the above legislative changes a priority, and the 
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 Indeed, physician-recorded chart notes are often considered to be conclusive evidence: see SS. 
Kwak, “The Medical Accidents Compensation Act Should No Longer Be Delayed”, 29, August 2007, 
Korean Doctors’ Weekly, at http://www.docdocdoc.co.kr/news/. 
58
 A position which was certainly shaken by the physicians’ general strike of 2000, which was received 
with greatly divergent degrees of support by the public: SN Kang, “Professional Medical Ethics in the 
Korean Context: Towards a Moral Contract” in SY Song, YM Koo & D Macer (eds.), see note 9, 294-
297. 
59
 See Ahn v. Yonsei University, 13 December 1988, 85 Da Ka 1491 (Kor SC), and Hong et al. v Yonsei 
University, 27 July 1993, 92 Da 15031 (Kor SC). 
60EJ Jeong, “The Government Opposed to the Compensation in Medical Accidents Act”, October 2007, 
No. 1991, Korean Hospital News, at p. 3. 
61SK Kim, “The Ministry of Health and Welfare Actually Opposed to the ‘Shift of the Burden of 
Proof’”, October 2007, Korean Doctors’ Weekly, available at http://www.docdocdoc.co.kr/news/. 
(2008) 5:2 SCRIPTed 
 
280
most recent session of the Assembly ended in May 2008 without their passage 
(meaning that they will have to be re-introduced if they are to be realised).62  The sub-
committee is concerned about the opposition that will be aroused, not only in the 
National Assembly, but also in the public.  Indeed, on 11 October 2007, the Korean 
Medical Association, the Association of Korean Oriental Medicine, the Korean 
Dental Association and the Korean Assistance Nurses Association issued a Joint 
Statement expressing their strong objection to some of these reforms and threatening 
to return their licenses if these reforms were passed unaltered.  One might have little 
sympathy for physicians resisting the introduction into their basic governing 
instrument of a duty to explain (dialogue and engage with patients) and thereby show 
respect, but one might equally have sympathy for their position with respect to the 
shift of the burden of proof in negligence cases.  One might also have sympathy for 
the patients themselves, for such a move might well lead physicians to practise 
“defensive medicine”,63 which would negatively affect the delivery of healthcare to 
the Korean public. 
Given the instruments introduced, the resistance generated against them, and their 
failure to achieve promulgation in the most recent legislative session, it is unclear 
what path Korea is on (ie: whether it is slipping toward individualism, clinging to old 
practices with autonomy as a rhetorical tool, or adopting Yi’s modified therapeutic 
relationship approach).  The early evidence, which includes the above attempted legal 
reforms and increased medical litigation, might suggest the former, but some of the 
evidence is categorical.  For example, in the transplantation context, Confucian 
concepts of familialism are still important.  Generally, Korea is in a state of flux the 
trajectory of which will become clearer in the coming years. 
3. The Research Setting: Ethical Oversight and Recent Governance 
Activity 
With the commencement of the Human Genome Project in 1990 and the rise to fame 
of Dolly the Sheep in 1997, interest in biotechnologies and their potential for medical 
applications took off around the world.  Korea was no exception, adopting a platform 
of biotechnology and information technology development as a means of economic 
development.64  There followed an impressive array of research activity.  But at the 
height of the euphoria, Korea experienced a singular, socially defining and polarising 
                                               
62See SJ Ko, “Committee of Health and Welfare Reserve the Review of the Draft Medical Services 
Law”, 30 January 2008, available at http://www.medigatenews.com. 
63The term “ defensive medicine” refers to medical practices designed to avoid liability or avert future 
medical malpractice suits rather than to benefit the patient.  It often leads to increased though less well-
planned and medically warranted interventions, and thereby increases healthcare costs and, ironically, 
exposes patients to increased levels of risk (through excessive testing) without actually increasing the 
quality of care.  For more on this phenomenon, see the definitions in MedicineNet 
(http://www.medterms.com/script/main/art.asp?articlekey=33262), the Online Medical Dictionary 
(http://cancerweb.ncl.ac.uk/cgi-bin/omd?defensive+medicine), and others. 
64For more on this policy, see Ministry of Science and Technology, Biotechnology 2007 (Seoul: MST, 
2007), which outlines Korea’s “Fundamental Plan for Biotechnology Development”, also known as the 
“Bio-Vision 2016 Plan”, which includes primary objectives including the intensification of core 
infrastructure for industrialisation, the uptake of global techniques, and the creation of an affluent bio-
economy.  This Plan is a follow-on from the 1994 plan called “Biotech 2000”. 
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incident – the Dr. Woo-Suk Hwang scandal.65  In this Part, we briefly examine (1) the 
meteoric rise of Dr. Woo-Suk Hwang and pre-scandal research governance landscape, 
(2) the new research governance regime that was formulated in the shadow of that 
success, namely the Bioethics and Biosafety Act 2005,66 (3) the cataclysmic fall of 
Hwang and his team, and (4) the legislative changes that have been proposed in the 
wake of the scandal.  The purpose of the investigation is to assess the impact of that 
scandal and consider the position of the modern Korean researcher and participant in 
the post-scandal era. 
3.1 ‘Our Mutual Friend’ – The Rise and Rise of Dr. Hwang 
As previously noted, Korea has adopted a policy of development through 
biotechnology.  Indeed, the biotech industry was being promoted as early as the 1980s 
through the Genetic Technology Support Act 1983,67 which Act coloured the 
environment thereafter.68  Although many factions of Korean civil society expressed 
concerns about the possible dangers of biotechnologies and their advancement in the 
reproductive context at the turn of the millennium,69 they were largely drowned out 
by the public enthusiasm for both science-led economic development and the national 
honour that scientific leadership would generate.70  Their concerns were further muted 
by the apparent success of Dr. Hwang, then professor of biotechnology at the Seoul 
National University. 
In February 1999, Hwang announced that he had succeeded in cloning a cow by 
“somatic cell nuclear transfer” (SCNT).  Though he failed to offer any scientifically 
verifiable data (claiming that he did not keep careful records because he did not think 
                                               
65Of course, the UK experienced its own scandal in the biomedical research context, namely Alder Hey 
and Bristol.  For more on this incident, see D Hall & J Lilleyman, “Reflecting on Redfern: What Can 
We Learn from the Alder Hey Story?” (2001) 84 Archives Disease Childhood 455-456, J Robinson & 
P Furness, “In the Wake of Alder Hey”, 17 April 2004, Guardian, at 
http://www.guardian.co.uk/society/2004/apr/17/medicineandhealth.comment, K Liddell & A Hall, 
“Beyond Bristol and Alder Hey: The Future Regulation of Human Tissue” (2005) 13 Medical Law 
Review 170-223, A Plomer, The Law and Ethics of Medical Research (London: Routledge Cavendish, 
2005), ch. 5. 
66Law No. 7150, adopted 29 January 2004, last amended March 2005. 
67Law No. 3718, adopted December 1983, re-enacted as the Biotechnology Support Act 1995, Law No. 
4938, adopted in January 1995. 
68The only oversight provision contained in this Act was s. 15, which directed the government to issue 
biotech research guidelines to prevent biohazards and ethical problems; none were forthcoming until 
1997 when the government issued the Guidelines on Recombinant DNA Experiments, Ministry of 
Health and Welfare, 22 April 1997, Public Notice No. 1997-22.  These Guidelines contained only a 
single provision on ethical control of biotech research: Article 23 stated that the head of the ministry, 
agency or institute, together with industry, should develop measures to prevent ethical problems that 
might be caused by biotech experiments. 
69Note the Korean National Commission for UNESCO, Report of the 2nd Korean Consensus 
Conference on Cloning, September 1999, Seoul, available at http://www.unesco.or.kr/cc/eng.html, 
which called for a comprehensive but temporary ban on all attempts to clone any human life forms, 
including pre-embryos. 
70See SD Yi, “Legalising Embryo Cloning in the Midst of a Paralysed Public Discourse” (2006) 11 
KIATS Theory Journal 58-66. 
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the research was of major importance),71 the many publicity events that followed 
turned him into a national hero, the media stoking the public’s imagination of the 
economic prospects ahead.  Between September 1999 and August 2000, the Ministry 
of Science & Technology (MOST) awarded him US$1.6 million to mass produce 
high-capacity dairy cows by SCNT.  Although the project failed completely, Hwang’s 
reputation remained intact not least because of his many, well-timed public 
announcements.72 
 
In February 2004, the euphoria grew and Hwang shot to global fame when he 
published a paper in Science to the effect that his team had managed to clone a human 
embryo from which they had cultivated embryonic stem cells.73  He claimed that, 
using 242 unfertilised human eggs from 16 donors, they had created a human embryo 
through SCNT and had extracted stem cells from that embryo.  Although ethical 
concerns were raised,74 and despite declaring that they would discontinue their 
research until national legislation was in effect, Hwang’s team resumed in October 
2004 and published another paper in 2005,75 in which they claimed to have created, 
using 185 unfertilised human eggs, eleven patient-specific, immune-matched human 
embryonic stem cells by SCNT.  In short, he claimed to have created tailored stem 
cells for a patient, raising exciting possibilities for personalised therapies as well as 
commercialisation. 
The announcement of this most recent breakthrough cemented Hwang’s superstar 
status in Korea, made him the envy of biotech scientists around the world, and, it has 
been argued, prompted the government to “sanctify” his research and to deliberately 
set out to make him a national hero (nominating him as a “Supreme Scientist” and 
providing him with special guards).76  Korean Air gave him two first class tickets 
valid for 10 years.  Ethicists were all too eager to celebrate his work and clamoured to 
join his World Stem Cell Hub.  As a consequence of this celebrity, there could be 
                                               
71A common criticism at the time was that his achievements were never properly documented: see P 
Shanks, “The Hwang Saga Continues: A Genetic Crossroads Exclusive” (2006) at 
http://geneticsandsociety.org/article.php?id=2620. 
72For example, he declared that he would attempt to clone a Siberian tiger, the national symbol of 
Korea, as well as sterilised miniature pigs (for which he received US$5.5 million), and BSC-resistant 
cows (for which he received US$4.3 million): Board of Audit, An Intermediate Briefing on the 
Inspection of Government-Funded R&D Projects: Pertaining to Dr. Hwang Woo Suk’s Execution of 
Research Projects (Seoul: Republic of Korea, 2006). 
73WS Hwang et al., “Evidence of A Pluripotent Human Embryonic Stem Cell Line Derived From a 
Cloned Blastocyst” (2004) 303 Science 1669-1674. 
74D Cyranoski, “Korea’s Stem Cell Stars Dogged by Suspicion of Ethical Breach” (2004) 429 Nature 
3, YM Koo, “A Research Ethics-Based Analysis of the Korean Scientists’ Human Embryonic Stem 
Cell Research” (2004) 5 Journal of the Korean Bioethics Association 1-12, and Korean Bioethics 
Association, “Research in Medical Science and Biotechnology Must be Conducted in Accordance with 
Bioethical Principles” (2004), available at http://www.koreabioethics.net/pub.htm. 
75WS Hwang et al., “Patient-Specific Embryonic Stem Cells Derived from Human SCNT Blastocysts” 
(2005) 308 Science 1777-1783.  The continued perceived merit of his work is somewhat surprising 
given his claims that it was possible to give every patient the treatment with no immune reactions. 
76SD. Yi, see note 70, and M. Cho et al., “Lessons of the Stem Cell Scandal” (2006) 311 Science 614. 
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little criticism about the work, and Hwang rebuffed those he deigned to respond to at 
all, making it almost impossible to instigate serious debate in Korea.77 
This discursively oppressive environment does not mean that Hwang and his team 
conducted their “research” in a regulatory vacuum.  Though there was not much in the 
way of binding rules, there existed the MOHWFA Guidelines for Good Clinical 
Practice 1987,78 the KHIDI Guidelines on Human Stem Cell Research and 
Supervision 2001,79 the KMA Guidelines of Ethics for the Medical Professional 
2001,80 and the SCRC Guidelines for Review of Research Proposals 2003.81  
Additionally, in response to a 1998 allegation of human cloning at the Kyunghee 
Fertility Clinic, the Korean Medical Association struck an Investigative Committee 
(on which Hwang sat),82 which led to issuance of the Guidelines on Research on 
Cloning Lives 1999.83  Article 4 prohibits (1) research on human embryos for cloning 
purposes, (2) implantation of cloned embryos into a woman’s uterus, and (3) 
experimentation on embryos after 14 days post-fertilisation.  Article 8 prohibits the 
trading of sperm, eggs or somatic cells.  Many of these were at least partially relevant, 
suffering rather from poor monitoring and general ineffectiveness.  
3.2 ‘A Fine Balance’ – Ethical Oversight and Biotech Promotion in the New 
Regime 
Hwang’s international stature was in zenith, and with it general interest in biotech 
development, when the Bioethics and Biosafety Act 2005 (BBA 2005) neared 
                                               
77For more on the elevation of Hwang and the impossibility of serious ethical debate, see SD Yi, ibid, 
SY Song, see note 2, P Shanks, see note 71, and Editors, “Human Cloning and Scientific Corruption” 
(2006) 11 The New Atlantis 113-117. 
78Ministry of Health and Welfare, 28 December 1987, Public Notice No. 1987-87.  These guidelines 
are intended to protect human subjects of clinical drug trials, and are directed at research institutions 
and pharmaceutical companies.  Made binding in 1995 (Ministry of Health and Welfare, 27 July 1995, 
Public Notice No. 1995-39), and amended in 2000 to bring them in line with the International 
Conference on Harmonisation (Korean Food and Drug Administration, 4 January 2000, Public Notice 
No. 1999-67), these guidelines articulate the need for local ethical oversight, stating that documents, 
particularly consent documents, must be reviewed, and that special attention must be paid to trials that 
may include vulnerable subjects (ie: people who may be unduly influenced by the expectation of 
benefits or retaliatory responses from within a hierarchy) (Article 7). 
79Korean Health Industry Development Institute, Guidelines on Human Stem Cell Research and 
Supervision, adopted September 2001. 
80Korean Medical Association, Guidelines of Ethics for the Medical Profession, adopted November 
2001.  These are non-statutory professional rules which the KMA have the power to enforce with 
sanctions.  They reiterate the physician’s general duties to act ethically and direct physicians to secure 
consent to treatment (Article 23), refrain from trading in human eggs (Article 55), and limit cloning 
research to curing and preventing specific diseases (Article 68).  They also recommend the 
establishment of ethics committees in hospitals and research institutes (Articles 74-75). 
81Stem Cell Research Centre, SCRC Guidelines for Review of Research Proposals, adopted May 2003.  
Applicable to any research which the SCRC funds, these require that stem cell research be supported 
by surplus IVF embryos that are about to be discarded, and they prohibit the production of human 
embryos for stem cell research. 
82For more on this, see JS Kim, “The Position of the Korean Medical Association on Human Cloning 
Research” (1999) 42 Journal of the Korean Medical Association 826-829. 
83
 Korean Medical Association, Guidelines on Research on Cloning Lives, adopted May 1999. 
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completion.  In fact, the BBA 2005 was the culmination of a series of attempts by 
competing stakeholders (MOHWFA, the National Assembly’s Committee on Health 
and Welfare, bioethicists, certain NGOs versus MOST, which sought to establish its 
pre-eminence in the field of biotechnology, the National Assembly’s Committee of 
Science, Technology, Information and Telecommunication, scientists) to introduce 
bioethical legislation in Korea.84  Despite the turf wars that marked its creation, the 
BBA 2005 was eventually passed and went into effect on 1 January 2005. 
 
From an administrative and procedural perspective, the BBA 2005 establishes a 
National Bioethics Committee (ss. 6-8), requires research institutions to create 
Institutional Review Boards (ss. 9-10), and directs the Ministry to perform oversight 
of research institutions (ss. 18-21 and 38-44, 47).  From a more substantive point of 
view, the BBA 2005 addresses cloning (ss. 11 and 22-23), chimera production (s. 12), 
embryo production, storage, disposal and research (ss. 13-17, 20, 21), DNA testing 
(ss. 24-30), DNA banking and genetic information protection (ss. 31-35), and gene 
therapy (ss. 36-37).  Finally, the BBA 2005 contains provisions imposing sanctions 
for breaches of the rules (ss. 49-55). 
As a consequence of both the Hwang success and the negotiations undertaken 
between the two primary drafters (MOHWFA and MOST), what was ultimately 
adopted by the National Assembly was a reproductive medicine and biotech research 
regime with a dual function.  Its two roles are well articulated in s. 1, which states: 
This Act aims to enhance the health of human beings and the quality 
of human life by creating conditions that allow for the development 
of life sciences and biotechnologies that can be used to prevent or 
cure human diseases.  Additionally, this Act aims to protect human 
dignity and to prevent harm to human beings by ensuring that these 
life sciences and biotechnologies are developed safely and in 
accordance with the principles of bioethics. 
This duality is further recognised in s. 4, which states that the national or regional 
governments shall adopt all necessary measures to deal effectively with bioethical and 
biosafety problems that may arise during the development and utilisation of life 
sciences and biotechnologies.  For present purposes, it is the balancing of these two 
roles – that of promoting biotech development, on the one hand, and of protecting 
human dignity and patient safety, on the other – that is of interest, for the outcome of 
this balancing says something about the direction of Korean reproductive medical 
practice and research. 
                                               
84It was preceded by the unsuccessful work of the Korean Bioethics Advisory Commission and by 
some 12 aborted attempts by various factions within the Korean legislative community to introduce 
legislation: see SG Han et al., “New Cloning Technologies and Bioethics Issues: The Legislative 
Process in Korea” (2003) 13 Eubios Journal of Asian and International Bioethics 216-219.  For more 
on the legislative process, see SH Gwak, “The Legislation of the Bioethics and Biosafety Act and 
Policy Issues” (Winter 2003) Technology Trends in the Health Industry 152-162, YR Um, “South 
Korea: Human Embryo Research” (2003) 12 Cambridge Quarterly of Healthcare Ethics 268-278, YR 
Um, “Dispute Over Scientific Research Involving Human Embryos in South Korea” in SY Koo, YM 
Koo & D Macer (eds.), see note 9, 56-57, and HK Kim, “Bioethics and Biosafety Law in Korea” 
(2004) 13 Journal of the Association of Policy Studies 45-71, who argues that the National Assembly 
attached more importance to the development of biotechnology than to its ethical control. 
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Although the MOST didn’t get everything it wanted, the BBA 2005 contains a 
number of features which strongly enhance Korea’s capability to undertake cutting 
edge research, particularly embryonic and stem cell research, thereby facilitating the 
policy of development through biotechnology.  First, it classifies embryos according 
to the manner in which they are produced.  Subsection 2(2) defines “embryos” as a 
fertilised egg from the moment of fertilisation to the point at which all organs have 
developed.  Subsection 2(3) defines “remaining embryos” as embryos that are created 
through IVF procedures but not implanted in a woman.  Subsection 2(5) defines 
“somatic cell embryo clones” as embryos formed by the act of somatic cell nuclear 
transfer (SCNT).  It then requires a different purpose for the production of these 
different objects, and regulates them in different ways.  For example: 
• Embryos are regulated by s. 13, which states that no one shall provide sperm 
or oocytes for the purpose of financial reward, and no embryo shall be 
produced other than for the purpose of pregnancy (with the consequence that 
no artificial insemination shall be undertaken for research purposes).  
However, under s. 16, embryos can be stored for up to 5 years (with the 
consent of the originators), after which they must be destroyed, unless they are 
to be used for research.  As such, given that the almost inevitable consequence 
of IVF treatment is the production of excess embryos, embryos are indeed 
created with the (tacit) knowledge that some will be destined for research, and 
ss. 19 and 20 address the procedures for transferring such embryos from 
“embryo producing institutions” to “embryo research institutions”. 
• According to s. 17, remaining embryos are those that have passed the storage 
period, and such embryos may be used – prior to the appearance of a 
“primitive streak” – for research, but only for research (1) aimed at developing 
contraception and infertility treatments, (2) aimed at curing rare or incurable 
diseases as decreed by the President, or (3) approved by the President after 
being reviewed by the National Bioethics Committee. 
• Conversely, somatic cell embryo clones are regulated by ss. 22 and 23.  These 
provisions stipulate that no one shall conduct SCNT other than for research 
aimed at curing rare or currently incurable diseases, as decided by the 
President after review by the National Bioethics Committee. 
However, as should be clear from the above, embryos created by one means or for 
one purpose can find their way into another category, thereby opening up their use 
dramatically. 
The second feature which clearly enhances the pursuit of biotechnology research is 
that, although the BBA 2005 clearly prohibits reproductive cloning (s. 11) and 
implantation of an animal’s somatic cell nucleus into a human oocyte whose nucleus 
has been removed (s. 12(2)), it contains no provision prohibiting the act of implanting 
a human nucleus into an animal oocyte.  As such, it has been claimed that Korea is the 
first country in the world to permit nuclear transfer between species.85 
Third is the deployment of consent within the regime.  At first blush, the BBA 2005 
appears to embrace fully individual autonomy insofar as it erects rights of consent and 
self determination.  For example, with respect to reproductive treatment, s. 15 states 
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that medical institutions which collect sperm or oocytes to produce an embryo shall 
obtain written consent from both sperm and oocyte donors, the artificial insemination 
patient and her spouse.  It then goes on to outline the content of the written consent, 
which must include: 
(1) details of the purpose for producing the embryo (ie: it must be for 
implantation); 
(2) details of the retention period for the embryos; 
(3) details of the embryo disposal procedures; 
(4) an inquiry about whether consent is given to use remaining embryos 
for purposes other than pregnancy; and 
(5) information on the procedures for withdrawal of consent, the 
protection of consenter information, and other necessary information 
set by the Ministry. 
 
 
However, several aspects of the consent provisions suggest that research enablement 
was a prime motivator.  For example, the key self determination provision near the 
beginning of the instrument (s. 5) appears to place the patient in a rather passive 
position of “becoming” the subject of research.  Additionally, under s. 17, a new 
consent to use remaining embryos for research is only required if they are intended to 
be used before the 5-year storage period has run its course; in short, the originator 
appears to lose control after 5 years. 
The above features serve to make the BBA 2005 a very liberal (open) regime as far as 
governance of biotech development (ie: embryo research and SCNT related thereto) is 
concerned, though it might be unfair to characterise it as radically different from 
regimes which exist in other jurisdictions.  However, in light of this liberal approach, 
issues of management and oversight (or a means to address ethical concerns and 
ensure patient safety) is critically important.  In short, the decision-making and 
monitoring frameworks that are erected and their overall effectiveness are key. 
At the outset, s. 4 directs researchers to “endeavour” to safeguard human dignity and 
to carry out their work in accordance with the “principles of bioethics and biosafety”.  
However, aside from this reference to that popular but amorphous term (dignity),86 
the BBA 2005 contains no explicit reference to any mid-level guiding principles nor 
to any relevant international instruments.  All that is offered are the consent 
provisions and the specific prohibitions identified above and the admonition that care 
must be exercised when storing, handling and disposing of remaining embryos (s. 
21(2)), and research must be halted or appropriate measures taken when research 
poses a significant or potential threat to “bioethics or biosafety” (s. 21(3)). 
Section 6 calls for the establishment of a National Bioethics Committee (NBC), which 
is to review matters implicating bioethics and biosafety, including policies, research 
projects on remaining embryos or involving SCNT, DNA test prohibitions, gene 
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therapy target diseases, and other issues of social or moral significance implicated by 
life sciences research.  The NBC was formed some three months after the BBA 2005 
came into force,87 and was composed of seven departmental Ministers, seven 
research/academic/industry experts, and seven civil society represents.88  However, it 
is not clear whether the NBC is intended to be primarily a policy advisory committee, 
or a research oversight committee.  Given its general elevation from the daily 
activities of research labs, it is probably best equipped as the former, and so the BBA 
2005 also calls for the establishment of Institutional Review Boards (IRBs) by each 
Embryo Research Institution (ERI). 
Section 9 states that IRBs are to review all matters relating to research undertaken by 
their host ERI, including ethical and scientific validity, consent measures, safety 
measures, and other matters.  The IRB must approve research protocols before 
commencement of work (s. 19(2)).  Additionally, where there is a serious threat or 
potential threat “to bioethics and biosafety” due to research being undertaken at the 
host ERI, the IRB must be summoned to conduct a review (s. 9(3)).  Unfortunately, 
there is no elucidation of any mechanisms to alert the ERI when this is necessary, and, 
in any event, the IRB does not have an independent or “arms length” relationship with 
the host ERI insofar as the head of the ERI appoints the 5-9 members of the IRB (s. 
10). 
All ERIs must register with, and must meet the facility and personnel requirements set 
by the MOHWFA (s. 18).  Further, ERIs must submit an embryo research protocol to 
the MOHWFA before commencing work (s. 19(1)).  Neither the approval criteria, nor 
the evaluation process, nor the documents required are elucidated; they “shall be 
decided by the Ministry” (s. 19(4)).  Chapter 7 goes on to state that the MOHWFA 
may (1) conduct inspections, (2) demand reports from ERIs, (3) order the disposal of 
embryos, (4) order the improvement of facilities, (5) revoke ERI registrations or 
authorisations (after a hearing), and (6) issue fines for non-compliance (ss. 38-43).  
However, s. 47 states that the MOHWFA may delegate part of its authority, including 
managing ERIs, to the heads of other institutions, and can reward those institutions 
with financial compensation. 
Despite the weakness of the mechanisms put in place to promote “bioethics” – a term 
which remains conceptually vague and short of content – it is still conceivable that the 
oversight framework could function.  This would, of course, require a certain level of 
effectiveness and competence of those in supervisory roles.  Unfortunately, the NBC 
had no role in individual research projects, the operation of the IRBs was delayed, 
and, in any event, were either ineffective or utterly captured by vested interests.89  All 
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told, as found by the eventual NBC investigation, the IRBs performed poorly.90  Of 
course, they would not have been helped by the fact that no body was clearly assigned 
an inspectorate function. 
On the whole, the BBA 2005 might be characterised as a triumph of scientific 
interests, a common perception being that it attaches much greater importance to the 
development of biotechnology than to bioethics.  This may not be a completely fair 
characterisation, particularly given the many and complex interests that shaped its 
formulation, but the shortcomings of the BBA 2005, from an ethical oversight 
perspective, are apparent.  From a functional perspective, it did little to invigorate 
ethical debate or enforce ethically-grounded limitations on actions.91  As a 
consequence, Korea found itself embroiled in, and embarrassed by, the Hwang 
scandal. 
3.3 ‘That Was Then and This Is Now’ – The Unravelling of a National Icon 
Despite being muted, ethical questions about Hwang’s research – ranging from 
rumours about draconian egg donation demands/practices, to concerns about the 
validity of the scientific evidence, to worries about financial impropriety – were 
raised and would not go away.  One long-term sceptic, the Catholic Church of Korea, 
voiced its concerns regularly and announced a plan to raise funds for adult stem cell 
research.92  In the autumn of 2005, Dr. Ryu, a former collaborator, posted a 
confidential message about his suspicions of fabrication, and Dr. Schatten, a 
University of Pittsburgh researcher, ceased his collaboration, citing concerns about 
the egg donation process.  Later that month, a popular Korean investigative TV 
program, “PD Notebook”, reported that eggs had been obtained unethically.  Indeed, 
one interviewee stated that Hwang became very angry when she refused to donate her 
eggs, and claimed that, once she finally agreed, she donated eggs in the morning and 
then conducted research on them in the afternoon. 
A national discussion (finally) followed, as well as several investigations, most 
notably by the Seoul National University,93 the National Bioethics Committee,94 the 
Korean Board of Audit,95 and the Seoul Central District Prosecutors’ Office.96  By 
early 2006, it was concluded that: 
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 Egg Donation 
• some 2,221 eggs from some 138 women, were used in the research; 
• some women were introduced through an egg broker and almost 100 of them 
were paid; 
• at least two of the women (who donated some 31 eggs) were junior 
researchers under Hwang, who distributed consent forms to them and 
personally escorted at least one of them to the hospital for the egg extraction 
procedure; 
• extractions took place at four hospitals, and those sourced from the MizMedi 
Hospital did not undergo any IRB scrutiny whatsoever; 
• most of the women received no or insufficient information regarding possible 
side effects of hyper-stimulation, or were not consented at all; 
• many of the women received insufficient follow-up treatment; 
 
 
Scientific Fraud 
• co-authorships on the various research papers were offered arbitrarily (and 
apparently in exchange for favours given); 
• evidence was falsified, including the number of cell lines actually created and 
the photos used in support of the claims made such that there were no 
scientific data to prove any of their stem cell related claims; 
Embryo Abuse 
• given that Hwang’s research could contribute nothing to scientific 
understanding, the embryos that were used and/or created were wasted to no 
valuable end and were therefore shown no respect;97 
Financial Impropriety 
• Hwang had inappropriately mixed research funds with personal income and 
accounts; 
• Hwang had used research funds to pay exorbitant consultant honoraria., buy 
his wife a car, pay egg brokers, pay politicians, and, toward the end, bribe co-
researchers into silence; and 
• Hwang was unable to account for US$31.8 million in public money and 
US$6.2 million in private donations. 
Ultimately, Science retracted both of Hwang’s articles, Hwang was expelled from the 
Seoul National University, the Korean government rescinded its financial support, 
and Korean prosecutors indicted Hwang and certain co-researchers for fraud, 
embezzlement and breach of the new medical laws which had been adopted over the 
course of the saga.98  Hwang remains only partially contrite and still has fanatical 
support amongst the public. 
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3.4 ‘Brave New World’ – Redressing the Ethical/Promotional Balance? 
As the Hwang incident broke and devolved into scandal, attention was drawn anew to 
the risks of an uncritical devotion to the development of biotechnology, and the fatal 
weaknesses in the BBA 2005’s capability to govern effectively were exposed.  
Eventually, the Korean government admitted the need to amend research governance 
and a Standing Committee of the National Assembly was given two proposals to 
consider, one a “wholesale” amendment recommended by the MOHWFA,99 and the 
other a “partial” amendment prepared and supported by some 130 Members of the 
National Assembly.100  The MOHWFA also put before the Standing Committee the 
Reproductive Cells Utilisation and Supervision Bill.101  And pursuant to its powers, 
that Standing Committee voted in support of these instruments, which are now 
considered “priority items”. 
Given the terrific failures of the various IRBs to monitor Hwang’s research 
effectively over the preceding years, it is unsurprising that IRB oversight is addressed 
in the MOHWFA’s amending Bill (Bill 7702).  Section 9 encourages the 
establishment of IRBs in institutions which, though not generating stem cell lines, 
uses stem cell lines in the conduct of their research, which is intended to result in 
treatments for humans.  Section 11 states that, with respect to IRB governance, the 
MOHWFA will supervise and assess IRB action taken in response to executive 
orders.  Whereas hybridisation is permitted in the BBA 2005, Bill 7702 clearly 
prohibits nuclear transfer between species (s. 13).  With respect to stem cell research 
more particularly, s. 22 imposes on those producing or importing stem cell lines the 
need to register with the MOHWFA.  Section 23 states that where such institutions 
offer their lines to others, the proposed research has to go through IRB review.  
Section 24 sets boundaries for stem cell use, requiring that research be directed at the 
diagnosis, prevention or treatment of diseases, or at the characterisation and 
specialisation of stem cells themselves.  If other research objectives are envisioned, it 
must first receive scrutiny by the NBC and be followed by an order or permission 
from the MOHWFA.  In either case, the research must receive the assent of the 
relevant IRB. 
The Reproductive Cells Utilisation and Supervision Bill, which was clearly motivated 
by the deficiencies in the consent process that characterised the Hwang scandal, 
reiterates the right of self-determination.  Section 4 states that self-determination 
applies to decisions about whether to allow reproductive cells to be extracted or 
donated or used to produce embryos.  Additionally, the person who donates the cells 
(and his/her spouse) must be sufficiently informed about the potential side-effects and 
consequences of extraction and/or donation.  Subsection 14(1) stipulates that all egg 
donors must be over 20, must be independent (a term which is not specifically 
defined), and must be both physically and psychologically healthy.  If independence 
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is in question, the extraction must be considered and confirmed by the relevant IRB.  
Under s. 14(2) these criteria need not be met where the egg donation is part of the 
woman’s treatment for her own, or other women’s infertility, or where it is for 
research on a rare and intractable disease from which the woman suffers.  Egg 
donation for general research is forbidden, but supernumerary IVF eggs can be used 
for such research provided the donor has included in her written consent permission to 
do so (see s. 19).  Section 17 states that, where super-ovulation is relied on, the 
number of egg extractions and the minimum time which must pass between them are 
to be set by order of the MOHWFA.  Finally, s. 6 makes clear that neither the use nor 
offer of reproductive cells or embryos shall be induced by money or profit.  In short, 
reproductive cells cannot be bought or sold; commercial dealings are forbidden and 
only actual expenses are permitted to be recovered, although it should be noted that 
this provision is limited to dealings between researchers and donors; commercial 
transactions between labs are not addressed. 
Although Bill 7702 is characterised as a “wholesale” amendment, there are in fact no 
fundamental changes with respect to the government’s position on the importance of 
biotechnology to economic development.  Indeed, in many ways Bill 7702 lightens 
the administrative burden on stem cell researchers; where the BBA 2005 required 
both producers and users of stem cells generated through SCNT to register with and 
obtain approval from the MOHWFA (s. 23), Bill 7702 requires only producers to so 
register.  Researchers relying on stem cell lines already generated need only submit a 
research protocol to the embryo-producing institution.  Similarly, in the case of DNA 
testing for research purposes, the duty to report to the Minister is abolished (ie: only 
IRB review is necessary).  Additionally, although Bill 7702 directs the government to 
ensure that researchers comply with bioethical principles, it still fails to enunciate any 
underlying principles of bioethics and biosafety; it offers some directions and 
prohibitions, and it mentions human dignity (again without defining its use of the 
term), suggesting that human life has value, but there is no mechanism for balancing 
these values against research.  Moreover, this lacunae is not really filled by anything 
in the Reproductive Cells Utilisation and Supervision Bill. 
Would Hwang’s “research” have been caught earlier or stopped if this proposed 
regime had been in place?  In the absence of a dramatic dampening of public support 
for science and associated nationalist sentiment, and a simultaneous increase in a 
willingness to question and scrutinise research activities, a different course seems 
seriously in doubt.  In both proposals, control and support (for example for educating 
and training IRB members and researchers in bioethics) rests with the MOHWFA, an 
institution which proved spectacularly inept at this function during the Hwang era.  
Indeed, there is no evidence that either the MOHWFA or the (new) IRBs are 
approaching stem cell research and/or SCNT any more critically than in the past. 
3.5 Summary & Conclusion: Regulatory Inertia in the Research Setting 
The Hwang period – a period of national zenith and nadir, from a medical research 
perspective – constitutes a turbulent backdrop against which medical law reforms 
might be considered, and it is difficult to overstate the significance of Hwang to both 
the BBA 2005 and to the subsequent amendment proposals.  Despite extensive 
political jockeying and multiple drafts, it is perhaps not unfair (though certainly 
ironic) to suggest that the BBA 2005 did not receive the sober consideration it should 
have.  And it reflects the defects in its creation through an imbalance in its two core 
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objectives (ie: the uneasy alliance between biotech promotion and patient safety).  
That flawed regime and its more flawed application (in respect to Hwang) is central to 
the medical law crossroads at which Korea now stands. 
Clearly, biotechnology is (or promises to be) a dynamic and exciting vehicle for 
change, and medicine is one of its primary beneficiaries.  Korea at the turn of the 
millennium is an example of what can happen when one gets seduced by that promise.  
The objective of new legislative efforts in this field in Korea should be to temper the 
excitement and enforce a better balance between “value-rationality” and “goal-
rationality” conduct, the latter of which has held sway.102  Unfortunately, it is not 
clear that the new legislation (eg: Bill 7702 and the Reproductive Cells Utilisation 
and Supervision Bill) can, in the long term, redress the existing imbalance.  In short, 
the law in this area demonstrates a certain and regrettable “inertia”.  Having said this, 
we would not like to be taken as espousing the imposition of additional or more 
complex regulation.  Korea could achieve a better balance through a simple but clear 
instrument.  A valuable feature of that instrument, in addition to the provision of the 
proper training of monitors, could be the introduction of random inspections of 
research institutions and facilities by a statutorily empowered body. 
4. Conclusion: Drift and Inertia in Bio-Medical Governance 
We have examined the clinical setting and the research setting in Korea because both 
of these arenas have been the subject of intense legislative scrutiny in recent years, 
and have been the targets of rather dramatic reform proposals.  In the first case, the 
clinical setting, technology has played no small part in the motivation for change.  In 
the latter case, it is the very heart and being of the regime in consideration.  But 
despite the strikes and the scandals, the hurdles and abuses, and the almost frenetic 
political/legislative activity that has resulted, there has been no great paradigm shift in 
Korean medical law.  There has been a shift, but it has been more muted – even subtle 
– and it has manifested differently in the two arenas, taking them in curiously 
different directions. 
In the clinical setting, reform efforts (ie: amendments to the MSA 1951 and 
introduction of the Medical Accidents Compensation Bill) evince a “principle drift” 
insofar as they discloses a slow but steady growth in the recognition of individual 
patient rights and an erosion of the vaulted position of physicians.  This 
transformation is closely connected to evolutions in medical practice (eg: 
technologisation and specialization), and evolutions in society (eg: the rise of a 
contract culture).  These evolutions are transforming the physician-patient 
relationship from a traditional one of guardianship to a new one of partnership 
whereby a tacit treatment contract is entered into.  Although this reshaping appears to 
be in keeping with Western practices, one should be cautious about that claim.  The 
contours of the traditional manifestation of that relationship are not being 
precipitously abandoned in favour of an excessively individualistic emphasis; patient 
rights, which are founded on respect of persons, are important and need not be 
resisted in the Korean context, but it is important to recall the two-way and multiple 
duties that exist within that relationship.  We would argue that clinical reforms should 
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focus on the protection and re-construction of mutual respect, trust and empathy 
between physician and patient, and that some of the recently-introduced reforms, 
particularly those contained in the Medical Accidents Compensation Bill, fail to do so.  
Wholesale acceptance of the proposed reforms – which is unlikely given that the 17th 
Korean National Assembly has now been concluded – would represent a “drift” that 
takes Korea too far from its traditional values and practices, and would not 
necessarily result in more respect for patients or better protection of their rights. 
In the research setting, reform efforts (ie: amendments to the BBA 2005 and 
introduction of the Reproductive Cells Utilisation and Supervision Bill) represent 
some improvement over the old regime, but nonetheless evince a certain “inertia” 
insofar as they cling to the desire to promote biotechnology and not unduly hinder 
biotech development.  In short, the balance achieved between biosafety promotion 
and reproductive health, on the one hand, and biotech promotion, on the other, is still 
questionable.  This lack of transformation is probably the fault of Korea’s scientism, 
its ongoing desire to link economic development with biotech innovation, continuing 
public hope in the field, and powerful stakeholders with strong interests that resist 
ethical oversight and boundary-setting.  Nonetheless, we do not wish to criticise the 
proposed new regime too harshly; it is an improvement and there is some evidence of 
an attempt to re-balance.  The key, of course, is what happens next.  Will researchers 
once again be left in a largely unscrutinised position, or will the oversight framework 
be better deployed and supported?  These are questions that will require the 
generation of empirical evidence.  Parenthetically, given the nature of the regime and 
its intimate link with, indeed reliance on, reproductive medicine, we suggest that the 
purpose of pregnancy needs to play a greater role in shaping Korea’s biotechnology 
trajectory.103 
All told, we conclude that Korean medical law, at least as embodied in the two fields 
examined above, is characterised by “drift” and “inertia”.  Drift has seen the clinical 
setting exhibit an erosion of physician and family authority in both law and practice.  
This phenomenon has not been reproduced in the research setting, where inertia has 
ensured that, despite (best?) efforts to impose oversight, the reality is the continuation 
of a fairly lassaiz faire attitude, which appears unprepared to change dramatically.  As 
such, we claim that the current condition is a ‘tale of two standards’ inasmuch as the 
result has different implications for practitioners in each field.  One the one hand, 
physicians are being constrained, and stricter standards are being applied to their 
conduct.  On the other hand, researchers, though facing a new regime, are not 
labouring under similar constraints, and it is unclear that stricter standards will be 
applied. 
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